

URL: <https://stvp.stanford.edu/clips/innovation-pathway-for-bio-design>

Aneesh Chopra, Chief Technology Officer of the United States, describes how the government's new Innovation Pathway encourages bio-design innovation in the United States. According to Chopra, this new initiative will hopefully help the FDA adopt more forward leaning reforms in the application process.



Transcript

The question was whether or not the FDA's regulatory policies are shifting innovation overseas and it's a very thought question and I appreciate it.. The FDA has released a set of unprecedented transparency provisions to disclose what it is that they're doing operationally.. They haven't had any law changes in this administration except for the expansion of the ability to manage tobacco and some food safety items.. But in terms of what you're describing, it's the same FDA as it was years ago.. So the question is whether or not the FDA has been forward leaning enough in reform, so that it can encourage innovations to thrive in the U.S.. It is for that reason that in January they unveiled the innovation pathway.. A new strategy to streamline and simplify applications into the FDA that have the potential to serve big challenges in our current biomedical device space.. So we're hopeful the innovation pathway will address some of these concerns.. We've certainly heard a great deal of feedback and I can assure you, the leadership under Dr.. Hamburg is taking them seriously in looking for ways we can improve our internal capacities..